CEACAM6 is a prognostic biomarker and potential therapeutic target for gastric carcinoma

Guo Qing Ru, Yong Han, Wei Wang, Yuan Chen, Hui Ju Wang, Wen Juan Xu, Jie Ma, Meihua Ye, Xi Chen, Xiang Lei He, B. Györffy, Zhong Sheng Zhao, Dongsheng Huang

Research output: Contribution to journalArticle

2 Citations (Scopus)

Abstract

This study aims to investigate the prognostic power of carcinoembryonic antigenrelated cell adhesion molecule 6 (CEACAM6) in gastric cancer (GC) and its potential role in cancer development and progression. Data mining results show that CEACAM6 is overexpressed in gastric cancer and is correlated with lymph node metastasis. Subsequently, immunohistochemical staining was performed to determine CEACAM6 protein levels in paraffin gastric tumor specimens. Real-time reverse-transcriptionpolymerase chain reaction (RT-PCR) was conducted to detect CEACAM6 mRNA levels in fresh GC samples. CEACAM6 protein and mRNA levels were significantly up regulated in GC compared with paired normal mucosa. The IHC staining intensity of CEACAM6 was positively correlated with tumor size, Lauren's classification, vascular invasion, lymph node metastasis, distant metastasis, and TNM stage. CEACAM6 expression was inversely correlated with the five-year survival rate of GC patients. Cox multivariate analysis results demonstrated that the overall survival was independently correlated with CEACAM6 expression. A significant association was observed between CEACAM6 and distant metastases. Network analysis of downstream gene signatures revealed several hub genes such as SRC and DNM1L etc. which may mediating tumor promoting functions of CEACAM6. Further data mining discovered that Tamoxifen etc. could be therapeutic alternatives for gastric patients with CEACAM6 overexpression. Collectively, CEACAM6 overexpression is a common characteristic of GC and is associated with poor 5 year survival rate in GC. Besides, potential molecular mechanisms and treatment options were also provided.

Original languageEnglish
Pages (from-to)83673-83683
Number of pages11
JournalOncotarget
Volume8
Issue number48
DOIs
Publication statusPublished - Jan 1 2017

Fingerprint

Cell Adhesion Molecules
Stomach
Biomarkers
Carcinoma
Stomach Neoplasms
Therapeutics
Neoplasm Metastasis
Data Mining
Neoplasms
Survival Rate
Lymph Nodes
Staining and Labeling
Messenger RNA
Tamoxifen
Paraffin
Genes
Blood Vessels
Mucous Membrane
Proteins
Multivariate Analysis

Keywords

  • CEACAM6
  • Chemotherapeutics
  • Gastric carcinoma
  • Metastasis
  • Overall survival

ASJC Scopus subject areas

  • Oncology

Cite this

Ru, G. Q., Han, Y., Wang, W., Chen, Y., Wang, H. J., Xu, W. J., ... Huang, D. (2017). CEACAM6 is a prognostic biomarker and potential therapeutic target for gastric carcinoma. Oncotarget, 8(48), 83673-83683. https://doi.org/10.18632/oncotarget.19415

CEACAM6 is a prognostic biomarker and potential therapeutic target for gastric carcinoma. / Ru, Guo Qing; Han, Yong; Wang, Wei; Chen, Yuan; Wang, Hui Ju; Xu, Wen Juan; Ma, Jie; Ye, Meihua; Chen, Xi; He, Xiang Lei; Györffy, B.; Zhao, Zhong Sheng; Huang, Dongsheng.

In: Oncotarget, Vol. 8, No. 48, 01.01.2017, p. 83673-83683.

Research output: Contribution to journalArticle

Ru, GQ, Han, Y, Wang, W, Chen, Y, Wang, HJ, Xu, WJ, Ma, J, Ye, M, Chen, X, He, XL, Györffy, B, Zhao, ZS & Huang, D 2017, 'CEACAM6 is a prognostic biomarker and potential therapeutic target for gastric carcinoma', Oncotarget, vol. 8, no. 48, pp. 83673-83683. https://doi.org/10.18632/oncotarget.19415
Ru, Guo Qing ; Han, Yong ; Wang, Wei ; Chen, Yuan ; Wang, Hui Ju ; Xu, Wen Juan ; Ma, Jie ; Ye, Meihua ; Chen, Xi ; He, Xiang Lei ; Györffy, B. ; Zhao, Zhong Sheng ; Huang, Dongsheng. / CEACAM6 is a prognostic biomarker and potential therapeutic target for gastric carcinoma. In: Oncotarget. 2017 ; Vol. 8, No. 48. pp. 83673-83683.
@article{7cf6ece2e0444176945b007413093b3e,
title = "CEACAM6 is a prognostic biomarker and potential therapeutic target for gastric carcinoma",
abstract = "This study aims to investigate the prognostic power of carcinoembryonic antigenrelated cell adhesion molecule 6 (CEACAM6) in gastric cancer (GC) and its potential role in cancer development and progression. Data mining results show that CEACAM6 is overexpressed in gastric cancer and is correlated with lymph node metastasis. Subsequently, immunohistochemical staining was performed to determine CEACAM6 protein levels in paraffin gastric tumor specimens. Real-time reverse-transcriptionpolymerase chain reaction (RT-PCR) was conducted to detect CEACAM6 mRNA levels in fresh GC samples. CEACAM6 protein and mRNA levels were significantly up regulated in GC compared with paired normal mucosa. The IHC staining intensity of CEACAM6 was positively correlated with tumor size, Lauren's classification, vascular invasion, lymph node metastasis, distant metastasis, and TNM stage. CEACAM6 expression was inversely correlated with the five-year survival rate of GC patients. Cox multivariate analysis results demonstrated that the overall survival was independently correlated with CEACAM6 expression. A significant association was observed between CEACAM6 and distant metastases. Network analysis of downstream gene signatures revealed several hub genes such as SRC and DNM1L etc. which may mediating tumor promoting functions of CEACAM6. Further data mining discovered that Tamoxifen etc. could be therapeutic alternatives for gastric patients with CEACAM6 overexpression. Collectively, CEACAM6 overexpression is a common characteristic of GC and is associated with poor 5 year survival rate in GC. Besides, potential molecular mechanisms and treatment options were also provided.",
keywords = "CEACAM6, Chemotherapeutics, Gastric carcinoma, Metastasis, Overall survival",
author = "Ru, {Guo Qing} and Yong Han and Wei Wang and Yuan Chen and Wang, {Hui Ju} and Xu, {Wen Juan} and Jie Ma and Meihua Ye and Xi Chen and He, {Xiang Lei} and B. Gy{\"o}rffy and Zhao, {Zhong Sheng} and Dongsheng Huang",
year = "2017",
month = "1",
day = "1",
doi = "10.18632/oncotarget.19415",
language = "English",
volume = "8",
pages = "83673--83683",
journal = "Oncotarget",
issn = "1949-2553",
publisher = "Impact Journals",
number = "48",

}

TY - JOUR

T1 - CEACAM6 is a prognostic biomarker and potential therapeutic target for gastric carcinoma

AU - Ru, Guo Qing

AU - Han, Yong

AU - Wang, Wei

AU - Chen, Yuan

AU - Wang, Hui Ju

AU - Xu, Wen Juan

AU - Ma, Jie

AU - Ye, Meihua

AU - Chen, Xi

AU - He, Xiang Lei

AU - Györffy, B.

AU - Zhao, Zhong Sheng

AU - Huang, Dongsheng

PY - 2017/1/1

Y1 - 2017/1/1

N2 - This study aims to investigate the prognostic power of carcinoembryonic antigenrelated cell adhesion molecule 6 (CEACAM6) in gastric cancer (GC) and its potential role in cancer development and progression. Data mining results show that CEACAM6 is overexpressed in gastric cancer and is correlated with lymph node metastasis. Subsequently, immunohistochemical staining was performed to determine CEACAM6 protein levels in paraffin gastric tumor specimens. Real-time reverse-transcriptionpolymerase chain reaction (RT-PCR) was conducted to detect CEACAM6 mRNA levels in fresh GC samples. CEACAM6 protein and mRNA levels were significantly up regulated in GC compared with paired normal mucosa. The IHC staining intensity of CEACAM6 was positively correlated with tumor size, Lauren's classification, vascular invasion, lymph node metastasis, distant metastasis, and TNM stage. CEACAM6 expression was inversely correlated with the five-year survival rate of GC patients. Cox multivariate analysis results demonstrated that the overall survival was independently correlated with CEACAM6 expression. A significant association was observed between CEACAM6 and distant metastases. Network analysis of downstream gene signatures revealed several hub genes such as SRC and DNM1L etc. which may mediating tumor promoting functions of CEACAM6. Further data mining discovered that Tamoxifen etc. could be therapeutic alternatives for gastric patients with CEACAM6 overexpression. Collectively, CEACAM6 overexpression is a common characteristic of GC and is associated with poor 5 year survival rate in GC. Besides, potential molecular mechanisms and treatment options were also provided.

AB - This study aims to investigate the prognostic power of carcinoembryonic antigenrelated cell adhesion molecule 6 (CEACAM6) in gastric cancer (GC) and its potential role in cancer development and progression. Data mining results show that CEACAM6 is overexpressed in gastric cancer and is correlated with lymph node metastasis. Subsequently, immunohistochemical staining was performed to determine CEACAM6 protein levels in paraffin gastric tumor specimens. Real-time reverse-transcriptionpolymerase chain reaction (RT-PCR) was conducted to detect CEACAM6 mRNA levels in fresh GC samples. CEACAM6 protein and mRNA levels were significantly up regulated in GC compared with paired normal mucosa. The IHC staining intensity of CEACAM6 was positively correlated with tumor size, Lauren's classification, vascular invasion, lymph node metastasis, distant metastasis, and TNM stage. CEACAM6 expression was inversely correlated with the five-year survival rate of GC patients. Cox multivariate analysis results demonstrated that the overall survival was independently correlated with CEACAM6 expression. A significant association was observed between CEACAM6 and distant metastases. Network analysis of downstream gene signatures revealed several hub genes such as SRC and DNM1L etc. which may mediating tumor promoting functions of CEACAM6. Further data mining discovered that Tamoxifen etc. could be therapeutic alternatives for gastric patients with CEACAM6 overexpression. Collectively, CEACAM6 overexpression is a common characteristic of GC and is associated with poor 5 year survival rate in GC. Besides, potential molecular mechanisms and treatment options were also provided.

KW - CEACAM6

KW - Chemotherapeutics

KW - Gastric carcinoma

KW - Metastasis

KW - Overall survival

UR - http://www.scopus.com/inward/record.url?scp=85031036200&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85031036200&partnerID=8YFLogxK

U2 - 10.18632/oncotarget.19415

DO - 10.18632/oncotarget.19415

M3 - Article

VL - 8

SP - 83673

EP - 83683

JO - Oncotarget

JF - Oncotarget

SN - 1949-2553

IS - 48

ER -